Targeted drugs for ovarian cancer are mainly used for patients with postoperative ovarian cancer or inoperable patients, and they need to be applied for a long time, and the specific situation needs to be judged comprehensively with the patient’s own physical condition. Commonly used targeted drugs for ovarian cancer include anti-angiogenic drugs (bevacizumab, etc.) and PARP inhibitors (olaparib, etc.), which can control the recurrence and metastasis of ovarian cancer, and slow down the tumor progression for inoperable patients. The corresponding drugs need to be applied for a long time to achieve the maximum therapeutic effect. Some patients may have obvious adverse reactions during the use of the drug, such as abnormal liver and kidney function, obvious decrease of white blood cells, etc. If the corresponding conditions are found, it is necessary to consult a doctor in time for observation, carry out standardized care under the guidance of a clinician, and stop using or reduce the dose of the drug if necessary.